Drug Index

C1 Esterase Inhibitor

Mechanism :

Believed to suppress contact system activation via inactivation of plasma kallikrein and factor XIIa, thus preventing bradykinin production.

Indication :

  • Hereditary angioedema

Contraindications :

History of anaphylactic or life-threatening hypersensitivity reactions to C1 inhibitor (human) or any component of the formulation.

Dosing :

6 to 11 years:
IV 500 units every 3 to 4 days; adjust dose based on individual patient response, up to 1,000 units every 3 to 4 days
Children ≥12 years and Adolescents:
IV 1,000 units every 3 to 4 days; if response is not adequate, doses up to 2,500 units (≤100 units/kg) every 3 or 4 days may be considered based on individual patient response.
HAE attacks (abdominal, facial or laryngeal), treatment:
Children ≥5 years and Adolescents:
IV: 20 units/kg.

Adverse Effect :

Headache, nausea, injection site reactions, nasopharyngitis, dizziness, erythema, pruritus, hypersensitivity reactions, flu-like symptoms.

Interaction :

Androgens: May enhance the thrombogenic effect of C1 inhibitors.
Estrogen Derivatives: May enhance the thrombogenic effect of C1 inhibitors.
Progestins: May enhance the thrombogenic effect of C1 inhibitors.

Hepatic Dose :

No dosage adjustments are recommended.
03/20/2024 21:28:20 C1 Esterase Inhibitor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0